VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2
- Registration Number
- NCT01289210
- Locations
- πΊπΈ
Stanford Cancer Center, Stanford, California, United States
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT01203943
- Locations
- π¨π¦
Vancouver General Hospital/University of British Columbia, Vancouver, British Columbia, Canada
πΊπΈUniversity of Louisville, Louisville, Kentucky, United States
πΊπΈBaylor College of Medicine, Houston, Texas, United States
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 44
- Registration Number
- NCT01201811
- Locations
- π¨π³
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
π¨π³Changhua Christian Hospital, Changhua, Taiwan
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 111
- Registration Number
- NCT01197560
- Locations
- πΊπΈ
Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
π¦πΊRoyal Adelaide Hospital, Adelaide, Australia
π¦πΊPrincess Alexandra Hospital, Woolloongabba, Australia
An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT01186939
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 267
- Registration Number
- NCT01178281
- Locations
- π΅π±
Centralny Szpital Kliniczny MSWiA, Warsaw, Poland
πΊπΈMayo Clinic, Rochester, Minnesota, United States
π§πͺUniversitaire Ziekenhuis Leuven Gathuisberg, Leuven, Belgium
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 226
- Registration Number
- NCT01177397
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈUCLA Neuro-Oncology Program, Los Angeles, California, United States
πΊπΈBillings Clinic, Billings, Montana, United States
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 13
- Registration Number
- NCT01169298
- Locations
- π―π΅
Imamura Bun-in Hospital, Kagoshima, Japan
π―π΅Nagoya Daini Red Cross Hospital, Nagoya, Japan
π―π΅Kumamoto University Hospital, Kumamoto, Japan
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT01163071
- Locations
- πΊπΈ
CTRC @ The Utah Health Science Center @ San Antonio, San Antonio, Texas, United States
πΊπΈKarmanos Cancer Center Institute, Detroit, Michigan, United States
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 50
- Registration Number
- NCT01146574
- Locations
- πΊπΈ
North American Research Institute, Azusa, California, United States
πΊπΈAcademic Medical Center, Los Angeles, California, United States
πΊπΈAcademic Medical Research Institute, Los Angeles, California, United States